Skip to main content

AirDuo Digihaler FDA Approval History

Last updated by Judith Stewart, BPharm on May 2, 2024.

FDA Approved: Yes (Discontinued) (First approved July 15, 2019)
Brand name: AirDuo Digihaler
Generic name: fluticasone propionate and salmeterol
Dosage form: Inhalation Powder
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma

AirDuo Digihaler (fluticasone propionate and salmeterol) is a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) combination therapy for the treatment of asthma in patients aged 12 years and older.

The digital inhalers from Teva Pharmaceuticals (ProAir Digihaler, ArmonAir Digihaler, and AirDuo Digihaler) will be discontinued from June 1, 2024. Asthma patients who use a Digihaler device should talk with their doctor about alternatives.

AirDuo Digihaler contains a built-in electronic module that records and stores information about inhaler events. AirDuo Digihaler may be used with, and transmits information to, a mobile App.

AirDuo Digihaler does not need to be connected to the app in order to use the medicine.

Development timeline for AirDuo Digihaler

DateArticle
Jul 15, 2019Approval FDA Approves AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder for Asthma

See also

AirDuo Digihaler (fluticasone propionate and salmeterol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer